Trial Profile
A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs PD-1 knockout T-cells (Primary) ; Cyclophosphamide; Interleukin-2
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 04 Mar 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Aug 2016 New trial record